GeneDx (WGS) versus Its Peers Financial Survey

GeneDx (NASDAQ:WGS) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its rivals? We will compare GeneDx to related businesses based on the strength of its valuation, institutional ownership, profitability, analyst recommendations, earnings, risk and dividends.

Institutional and Insider Ownership

61.7% of GeneDx shares are held by institutional investors. Comparatively, 56.8% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares GeneDx and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
GeneDx	$427.54 million	-$21.02 million	-18.87
GeneDx Competitors	$21.01 billion	$288.54 million	7.39

GeneDx’s rivals have higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for GeneDx and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	1	7	0	2.67
GeneDx Competitors	1851	7707	13270	815	2.55

GeneDx presently has a consensus price target of $90.86, indicating a potential upside of 32.29%. As a group, “Healthcare Providers & Services” companies have a potential upside of 11.89%. Given GeneDx’s stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than its rivals.

Volatility & Risk

GeneDx has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, GeneDx’s rivals have a beta of 0.98, indicating that their average share price is 2% less volatile than the S&P 500.

Profitability

This table compares GeneDx and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
GeneDx Competitors	-7.69%	-141.09%	-1.47%

Summary

GeneDx beats its rivals on 8 of the 13 factors compared.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.